Over 2.2 million Americans suffer from glaucoma — now a new procedure may relieve symptoms. Glaucoma is a disease in which there is a buildup of pressure behind the eye. The pressure often damages the ...
Glaucoma is a group of diseases that causes damage to an individual’s optic nerve, primarily from increased intraocular pressure. This increased pressure or ocular hypertension is usually caused by ...
iStent helps relieve eye pressure for glaucoma patients: "Smallest device approved for implantation"
MILWAUKEE — Glaucoma is a common and chronic disease that affects a person's vision. There are several ways of treating glaucoma, but there's an innovative new option for patients that reduces eye ...
The iStent inject was safe and effective for treating multiple types of primary open-angle glaucoma individually and in conjunction with cataract surgery, according to data published in Journal of ...
Glaucoma is a disease with no cure; left untreated, it can result in partial or complete loss of vision over time. It is not only the leading cause of blindness among African Americans and Hispanics ...
Camille Maertz has been living with glaucoma for nearly two decades. The disease can lead to blindness, and treating it with the traditional therapy of eye drops about a dozen times a day is often ...
Marcia Opstad and her husband, Greg, left their Cloquet home at 5:30 a.m. last Tuesday, headed for the Lakewalk Surgery Center. When they returned 4½ hours later, Marcia had a new lens in her right ...
WILMINGTON, NC (WECT) - A procedure for those with Glaucoma is making it easier to manage the degenerative eye condition on a day-to-day basis. Health officials say glaucoma is the second leading ...
NEW YORK (CBSNewYork)-- More than 2 million Americans have glaucoma – and half don't even know it. As CBS 2's Dr. Max Gomez reported, untreated glaucoma can lead to blindness. But a tiny new implant ...
Contraindications: The iStent inject is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior ...
ALISO VIEJO, Calif., June 25, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of ...
Micro eye stent developer Glaukos has filed to raise up to $86 million in an IPO to advance an already marketed product, as well as to further develop three additional ones in its pipeline. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback